Thank you to our speakers, sponsors, and delegates who joined us in Boston!
If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Continue the conversation at the European iteration of this meeting!
London, UK | 8-10th April, 2025
Successfully Navigate Regulations, Unveil Clear Routes to Commercialization & Optimize Test Selection to Accelerate Patient Access to Personalized Medicines for Improved Disease Outcomes in Oncology & Beyond
The 14th World Clinical Biomarkers & Companion Diagnostics Summit returned in September 2024 as the leading forum for diagnostic stakeholders. Attendees enjoyed an extended four-day agenda packed with new content and enhanced networking opportunities, uniting drug developers, diagnostics providers, payers and coalitions to share insights and accelerate biomarker-driven clinical trials.
Whether attendees were working with small molecules, large biologics, or other modalities, this year’s agenda was carefully curated to strengthen early disease biomarker discovery, clinical biomarker strategy, reimbursement clarity, and drug-diagnostics commercialization. Attendees joined over 500 fellow senior leaders across Biomarkers, Translational Medicine, Precision Medicine, Companion Diagnostics, Commercialization, Regulation, and more to drive the future of precision medicine and improve patient outcomes.
2024 Expert Speakers:
Ann Fish-Steagall
Senior Vice Preisdent - Patient Services & Healthcare Delivery
LUNGevity Foundation
Mark Gustavson
Senior Director & Global Head Computational Pathology Translational Science
AstraZeneca
Tricia Bal
Head - Oncology Precision Medicine, Global Commercial Strategy
Johnson & Johnson Services, Inc
What Was New for 2024:
A Whole New Day
Attendees got involved in 3 full days of data-driven content and interactive discussions this year, with an additional 3.5 hours dedicated to networking, providing actionable insights, industry connections, and cutting-edge knowledge to keep you ahead of the curve.
35 New Biopharma Speakers
Attendees heard from 35 new Key Opinion Leaders pioneering new data, advancing better technologies, and improving regulatory strategies in precision medicine from companies including AstraZeneca, Johnson & Johnson, Zentalis and more.
Brand New Content
Key topic areas included CDx in ADCs, LDT updates, generative AI and unsupervised learning models, transformative fluid biomarkers, non-invasive digital biomarkers and non-oncology biomarkers.
Companies that Attended in 2024:
2025 Partners
Other Events in the Series
